亚洲社会药学

本期目录

2024年, 第19卷, 第3期　刊出日期：2024-09-20 上一期    下一期

Select

Research on the Joint Reformation for Public Health Services, Medical Insurance and Medical Production Circulation from the Perspective of System Science Shi Jiatong, Sun Lihua 2024 (3):  209-215.  摘要 ( 125 )   PDF(427KB) ( 94 )   Objective To study the linkage points in the reform of public health services, medical insurance and medical production circulation and provide countermeasures for optimizing the reform. Methods The theory of system science was used to analyze the new emergent property of key linkage points in the main reform departments. Results and Conclusion The research found that four linkage points were not active, and all departments of the reform should strengthen their linkage in the following aspects. The departmental linkage in the decision-making mechanism should be strengthened, which requires to revise the assessment indicators of essential drugs in time, and carry out relevant policies. Besides, the linkage of various departments to supervise the use of medical insurance fund should be strengthened. Therefore, the National Health Commission (NHC) and National Medical Products Administration (NMPA) should play their supervisory roles. Lastly, the construction of adverse reaction data sharing platform should be improved. 相关文章 | 计量指标

Select

Research Progress and Suggestions on China’s Drug Registration Management Based on CiteSpace Knowledge Maps Li Yuan, Wang Yijie, Wang Shuling 2024 (3):  216-224.  摘要 ( 112 )   PDF(1593KB) ( 119 )   Objective To analyze the research status and hot spots in the field of drug registration in China, and to provide some suggestions for the follow-up research. Methods CiteSpace was used to conduct literature quantitative analysis on 684 related articles from 2012 to 2022, and the knowledge map was drawn. Based on this, the main characteristics and development trends of the related studies were summarized. Results and Conclusion The number of articles published was closely related to the regulatory policy of drug registration reform. The authors of these articles did not have good continuity. Besides, research hot spots were closely related to the actual work, which was mainly around the improvement of the review and approval policy, encouraging innovative drug research and development, improving the level of new drug development and other directions. The follow-up studies should further strengthen the continuity of research and inter-agency collaboration. In addition, biomedical registration may become a new research focus in the future. 相关文章 | 计量指标

Select

Research on the Problems and Countermeasures of the Landing of Negotiated Drugs Hu Xiaoting, Chen Binbin, Dong Li, Sun Lihua 2024 (3):  225-231.  摘要 ( 76 )   PDF(438KB) ( 69 )   Objective To provide reference for better landing of the negotiated drugs in the future. Methods Relevant data on the negotiated drugs in designated medical institutions and retail pharmacies from the website of the Medical Security Bureau was obtained, and then the allocation and problems of negotiated drugs were summarized and analyzed. Results and Conclusion The main problem for the landing of negotiated drugs is the difficulty of using them in medical institutions. First, there is a small number of designated medical institutions that can use some negotiated drugs. Second, the negotiated drugs vary greatly in the designated medical institutions. Lastly, some designated retail pharmacies do not supply the negotiated drugs. The difficulties in using the negotiated drugs can include subjective reasons and objective reasons. Retail pharmacies are not the official places where patients can use the negotiated drugs. Besides, if medical institutions do not supply and use negotiated drugs, it will pose a great risk to drug safety. Negotiated drugs should be used in designated medical institutions ultimately, which is conducive to safeguarding the rational drug use for patients. 相关文章 | 计量指标

Select

Suggestions on Improving China’s Breakthrough Therapy Designation System Wang Zuguang, Chen Yuwen 2024 (3):  232-236.  摘要 ( 72 )   PDF(941KB) ( 51 )   Objective To analyze the characteristics of breakthrough therapy designation (BTD) and its implementation in China, and to provide reference for the optimization of BTD system. Methods A comparative research method was used to study the content and implementation effect of BTD system in China and the relevant policies and implementation of the same procedures of drug regulatory authorities in the United States, Japan and the European Union. Then, the differences in policies and implementation results among these countries were analyzed to provide suggestions for the implementation and optimization of this system in China. Results and Conclusion China’s BTD system is implemented late and a small number of drugs has been approved. At the same time, there are problems such as insufficient guidance and communication from the agency to applicants, a broad application condition, single review mode, and lack of full-time personnel. Both the agencies and the applicants have limited experience due to the short implementation time of BTD system in China. There are still some problems despite we have learned a lot from the experience of other drug regulatory agencies. Therefore, based on our national conditions, we should strengthen the guidance of evaluation agency to applicants, optimize the eligibility criteria of BTD system, introduce the rolling review, and increase the number of professional liaisons, which can accelerate the development and marketing process of drugs with obvious clinical value, and finally to address unmet medical need. 相关文章 | 计量指标

Select

The Development and Experience of American Pharmaceutical Industry Associations and Its Enlightenment to China Zhang Yuanyuan, Tian Lijuan 2024 (3):  237-243.  摘要 ( 65 )   PDF(401KB) ( 56 )   Objective To study the development history and current situation of pharmaceutical industry associations in the United State and to provide reference for China’s pharmaceutical industry associations. Methods Literature research and comparative study were used to investigate the development history and current situation of pharmaceutical associations in the United States. Then, their characteristics and experiences were summarized. Some countermeasures and suggestions were put forward for the existing problems of pharmaceutical associations in China. Results and Conclusion The institutional environment of pharmaceutical associations in the United States is relatively good, reflecting the characteristics of emphasizing process management and neglecting entrance management with and the help of public supervision. At the same time, the government advocates market competition by adhering to the market-oriented services for the public. American pharmaceutical industry associations have strong innovation capacity and perfect credit system. Drawing on the experience of pharmaceutical industry associations in the United States, China should strengthen the construction of pharmaceutical industry associations. Firstly, the supervision mechanism should be improved. Secondly, these associations should have good partnerships with the government and offer the public the best services. Finally, the fund-raising mechanism of pharmaceutical industry associations should be optimized to ensure the innovative development of the pharmaceutical industry. 相关文章 | 计量指标

Select

Comparison of the Development of CDMO at Home and Abroad and Its Enlightment to China Zhao Meng, Huang Zhe 2024 (3):  244-250.  摘要 ( 87 )   PDF(794KB) ( 70 )   Objective To analyze the development status of contract development manufacturing organization (CDMO) at home and abroad, and to make some suggestions for the development of CDMO in China. Methods The relevant literature was searched and reviewed, and the development status of CDMOs in the United States, France, Japan and China was compared from the aspects of market scale, development process, development focus, advantages and disadvantages, and policy support. Then, some suggestions for the development of CDMO enterprises in China were summarized. Results and Conclusion Through the comparison of CDMO development at home and abroad, it can be seen that China started CDMO late, there were many technical barriers and its globalization layout were not sufficient. However, the development trend was good and it focused on the field of chemical drugs and biological drugs to constantly develop innovative drugs. China needs to continuously improve its own technical capabilities to carry out innovative research. Therefore, cost reduction and efficiency increase will be the key elements for the development of CDMOs, and they are expected to have a rapid and comprehensive development in the future. 相关文章 | 计量指标

Select

Development Trend and Prediction of Stem Cell Technology in China from the Perspective of Patent Liu Baijun, Fang Tingxiu, Liu Yue, Yuan Hongmei 2024 (3):  251-262.  摘要 ( 87 )   PDF(4741KB) ( 55 )   Objective To provide new ideas for the effective treatment of many serious diseases and to solve many major medical problems faced by mankind. Methods In this paper, the invention patents in the field of stem cells in China from 2010 to 2020 were taken as the research object, and the technology status quo in the field of stem cells was analyzed to predict the future development direction through quantitative analysis method. Results and Conclusion The development of stem cell technology in China is in a period of growth with great potential. Therefore, it is necessary to strengthen the ability of Chinese universities to combine production, education and research. Nowadays, the hotspots in stem cell technology are using culture medium to improve cell proliferation ability, production efficiency, and to induce differentiated cells. Meanwhile, the production efficiency of embryonic stem cells should be improved, and the immunomodulatory effect of embryonic stem cells can be exerted to screen drugs. Besides, the function of hematopoietic stem cells should be enhanced and apply mesenchymal cells in therapy. Since the potential technological gaps are the improvement of therapy, induced differentiation and efficiency of pluripotent stem cells, the improvement of progenitor cell proliferation and the control of cost, we should strengthen R&D investment in culture medium, embryonic stem cells and other technical fields, and achieve the purpose of reducing R&D costs and improving R&D efficiency. 相关文章 | 计量指标

Select

Suggestions on the Good Development of Pharmaceutical Cold Chain Logistics in China Wang Mingzheng, Wang Shuling 2024 (3):  263-271.  摘要 ( 77 )   PDF(837KB) ( 117 )   Objective To study the characteristics and problems of the development of cold chain logistics in pharmaceutical industry, and to provide a reference for the development of China’s drug logistics. Methods Literature analysis was used to investigate the development of drug cold chain logistics, relevant laws and regulations, and policies in China. Then, the problems of industry development were summarized and some suggestions were put forward by referring to the mature concept of international drug cold chain logistics system. Results and Conclusion China’s cold chain logistics in pharmaceutical field is growing, but it is still in the development stage. By increasing government support, scientific research investment and professional training, the comprehensive strength of drug cold chain logistics can be improved to a certain extent, and the safety of drugs can be guaranteed for the people. 相关文章 | 计量指标

Select

Research on the Improvement of Incentive Mechanism for Pharmaceutical Sales Personnel - Taking Company A as an Example Jia Fan, Tian Lijuan 2024 (3):  272-278.  摘要 ( 71 )   PDF(536KB) ( 63 )   Objective To analyze the improvement of the incentive mechanism of sales personnel in pharmaceutical company A, and to promote the smooth operation and further development of the company in a long term. Methods Compensation incentive, performance appraisal, welfare benefit, training incentive, promotion motivation and enterprise cultural inspiration were explored through questionnaires, telephone interviews and in-person interviews. Results and Conclusion This company’s incentive mechanism has problems in two aspects: Material incentives and spiritual incentives. As to the company’s characteristics and strategic development, the optimization countermeasures of incentive mechanism are proposed from the following three aspects: constructing a reasonable incentive system, establishing an efficient spiritual incentive mechanism, and implementing the dynamic incentive and differentiated incentive simultaneously. 相关文章 | 计量指标

Select

Meta-analysis of Cohort Studies on Clinical Efficacy of Icodextrin Peritoneal Dialysate Ren Hongyan, Wang Yaoling, Hui Xu, Li Xue, Zhao Kun, Huang Zhe 2024 (3):  279-290.  摘要 ( 82 )   PDF(15368KB) ( 54 )   Objective To evaluate the effect of real-world practices for icodextrin peritoneal dialysis solution on patients with end-stage renal disease (ESRD) by Meta-analysis. Methods The PubMed and Embase databases were systematically searched for real-world research literature on icodextrin peritoneal dialysate in the treatment of ESRD patients, and RevMan5.4 statistical software was used for Meta-analysis. Results and Conclusion 12 studies with 114 656 patients were included. Meta-analysis results showed that icodextrin peritoneal dialysis had good effects on mortality [RR = 0.72, 95% CI (0.62, 0.83), P < 0.001], congestive heart failure [RR = 0.67, 95% CI (0.52, 0.87), P = 0.003], and risk of new-onset diabetes [RR = 0.65, 95% CI (0.49, 0.86), P = 0.003], which was consistent with the Meta-analysis based on clinical trials. Meanwhile, there was no significant difference in PD technical failure rate [RR = 0.67, 95% CI (0.44, 1.00), P = 0.05], peritonitis [RR = 1.02, 95% CI (0.99, 1.05), P = 0.14], cardiovascular and cerebrovascular diseases [RR = 0.79, 95% CI (0.59], 1.05), P = 0.10], coronary artery disease [RR = 0.99, 95% CI (0.92, 1.07), P = 0.80], stroke [RR = 0.86, 95% CI (0.66, 1.10), P = 0.23], and atrial fibrillation [RR = 0.73, 95% CI (0.37, 1.44), P = 0.36]. However, it might increase the risk of hypertension [RR = 1.05, 95% CI (1.03, 1.07), P < 0.001]. Therefore, icodextrin can effectively reduce the risk of mortality, congestive heart failure, and new-onset diabetes, which is beneficial to ESRD patients. 相关文章 | 计量指标

Select

A Comparative Analysis of the Control Effect of Medical Expenses between General Hospitals and Traditional Chinese Medicine Hospitals from 2012 to 2021 Song Yamei 2024 (3):  291-306.  摘要 ( 79 )   PDF(5173KB) ( 57 )   Objective To analyze the changing trend of average medical expenses and structure in general hospitals and traditional Chinese medicine (TCM) hospitals and the effects and differences achieved by the two kinds of hospitals through controlling unreasonable growth of medical expenses, so as to provide reference for controlling the rapid rise of medical cost in public hospitals and optimizing the cost structure. Methods Based on the changes of related indicators of medical expense control from 2012 to 2021, the overall characteristics, changes of cost structure and trends of medical expenses in general hospitals and TCM hospitals were investigated. Results and Conclusion From 2012 to 2021, the increase of medical expenses in general hospitals and traditional Chinese medicine hospitals had slowed down, the proportion of drug revenue to medical income began to decline, and the medical service income increased. However, the proportion of inspection, test and sanitary materials income has increased instead of decreasing, but the management cost has decreased. The two kinds of hospitals have achieved certain cost control results, the structure of medical cost has changed greatly, and the technical service and labor value of medical personnel have been reflected to a certain extent. However, it is still necessary to explore a more scientific and reasonable cost control mechanism to promote the further optimization of medical cost structure. 相关文章 | 计量指标